Shots:The EC has approved Ogsiveo as a monotx. for adults with progressing desmoid tumors needing systemic treatmentApproval was based on global P-III (DeFi) trial (N=142) assessing Ogsiveo (150mg, BID, n=70) vs PBO (n=72) in adults with progressing desmoid tumorsTrial met its 1EP with 71% reduction in risk of disease progression & showed…